Myriad Genetics/$MYGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Myriad Genetics
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Ticker
$MYGN
Sector
Primary listing
Employees
2,700
Headquarters
Website
Myriad Genetics Metrics
BasicAdvanced
$689M
-
-$4.33
1.93
-
Price and volume
Market cap
$689M
Beta
1.93
52-week high
$28.28
52-week low
$3.76
Average daily volume
2.1M
Financial strength
Current ratio
1.422
Quick ratio
1.058
Long term debt to equity
22.211
Total debt to equity
39.835
Interest coverage (TTM)
-20.21%
Profitability
EBITDA (TTM)
-17.8
Gross margin (TTM)
70.43%
Net profit margin (TTM)
-47.45%
Operating margin (TTM)
-9.22%
Effective tax rate (TTM)
5.99%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-5.44%
Return on equity (TTM)
-70.03%
Valuation
Price to revenue (TTM)
0.812
Price to book
1.78
Price to tangible book (TTM)
4.14
Price to free cash flow (TTM)
-13.535
Free cash flow yield (TTM)
-7.39%
Free cash flow per share (TTM)
-0.547
Growth
Revenue change (TTM)
3.83%
Earnings per share change (TTM)
143.08%
3-year revenue growth (CAGR)
7.40%
3-year earnings per share growth (CAGR)
169.75%
What the Analysts think about Myriad Genetics
Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.
Bulls say / Bears say
Myriad surpassed Q2 revenue expectations, posting a 1% year-over-year rise to $213.1 million, and raised its full-year 2025 revenue outlook to $818–$828 million from $807–$823 million (Reuters)
Hereditary cancer testing in the Oncology segment powered 9% revenue growth and 10% volume growth year-over-year in Q2, demonstrating strong demand for the MyRisk with RiskScore solution (Reuters)
On July 31, the company secured a new $200 million credit facility, strengthening liquidity and financial flexibility to support precision oncology growth strategies (Reuters)
Q2 revenue increased by just 1% year-over-year and only 5% when excluding a $9.5 million headwind, highlighting ongoing weaker topline momentum in Myriad's core diagnostics segment (Reuters)
A $9.5 million headwind in Q2, resulting from UnitedHealthcare's decision to end GeneSight coverage and the sale of the European EndoPredict business, underscores continuing reimbursement and portfolio challenges (Reuters)
Despite raising full-year revenue guidance, Myriad left its 2025 adjusted EPS forecast unchanged at break-even ($0.02) to $0.02, reflecting limited prospects for short-term profitability improvement (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Myriad Genetics Financial Performance
Revenues and expenses
Myriad Genetics Earnings Performance
Company profitability
Myriad Genetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Myriad Genetics stock?
Myriad Genetics (MYGN) has a market cap of $689M as of September 18, 2025.
What is the P/E ratio for Myriad Genetics stock?
The price to earnings (P/E) ratio for Myriad Genetics (MYGN) stock is 0 as of September 18, 2025.
Does Myriad Genetics stock pay dividends?
No, Myriad Genetics (MYGN) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Myriad Genetics dividend payment date?
Myriad Genetics (MYGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Myriad Genetics?
Myriad Genetics (MYGN) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.